This page summarizes the status of research activities historically undertaken by BHI Therapeutic Sciences (BHITS). The information below is provided for educational and informational purposes only. Our products are investigational and have not been approved or licensed by the FDA, and these summaries are not claims of safety or efficacy for any disease or condition. In 2018, a study was registered on the clinicaltrials.gov database (NCT03735277) and reviewed by an Institutional Review Board (IRB). Mesenchymal stem cells (MSCs) and umbilical cord-derived cells are an active area of scientific research. Any proposed studies described here represent research efforts and are not statements about the effectiveness of any product. BHITS has previously prepared and submitted research study proposals to various scientific and governmental bodies. Such proposals reflect ongoing research interests only and do not constitute evidence that any product is safe or effective.
Nov. 30, 2021
“Retrospective Case Series Study of Dendritic Cell-Cytokine Induced Killer Cell Therapy in Previously Treated Subjects with Lymphatic Leukemia and Peritoneal Cancer”
Protocol #: BHI21-RCS-DCCIK Institute of Regenerative and Cellular Medicine IRB Approval #: IRCM-2-21-308
The documents linked below are research papers and study reports related to our historical research activities. They are provided for educational and informational purposes only and are not claims that any product is safe, effective, or approved for the treatment of any disease or condition.
Research report: chronic inflammation, aging, and back pain
Research report: spinal cord injury